^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QLS31904

    i
    Other names: QLS31904
    Associations

    News

    Trials
    Company:
    Qilu Pharma
    Drug class:
    CD3 agonist, DLL3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    QLS31904-101: Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=290, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    QLS31904
    over2years
    Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=290, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    QLS31904